| Bioactivity | LQZ-7F, a survivin dimerization inhibitor, induces spontaneous apoptosis and synergizes with Docetaxel in prostate cancer cells. LQZ-7F dose-dependently inhibits survival of both PC-3 and C4-2 cells with IC50s of 2.99 and 2.47 µM, respectively[1]. |
| Invitro | LQZ-7F could be hudrolyzed under acidic conditions[1].LQZ-7F (2.5 μM, 72 hours) displays cytotoxicity towards human cancer cells (PC-3, C4-2) with the IC50s of 2.99 μM and 2.74 μM, respectively[1].LQZ-7F effectively inhibits survival of all cancer cell lines with IC50 values ranging between 0.4 and 4.4 mM[2].LQZ-7F (2 μM, 24 hours) disrupts microtubule structure and cause mitotic arrest in P3 cells[2]. Apoptosis Analysis[1] Cell Line: |
| Name | LQZ-7F |
| CAS | 354543-09-2 |
| Formula | C14H7N9O3 |
| Molar Mass | 349.26 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |